STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 470 JPY | 0.00% |
|
-1.05% | -18.69% |
| 09/05 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| 13/03 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
Valuation
| Fiscal Period: July | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 46,285 | 39,013 | 49,873 | 56,361 | 28,905 | - | - |
| Enterprise Value (EV) 1 | 35,618 | 28,847 | 40,996 | 46,144 | 28,905 | 28,905 | 28,905 |
| P/E ratio | 127 x | -66.2 x | -25.5 x | 331 x | -22.2 x | -17.2 x | -16.4 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 22 x | 27.9 x | 2,267 x | 24 x | 28.9 x | 53.5 x | 53.5 x |
| EV / Revenue | 22 x | 27.9 x | 2,267 x | 24 x | 28.9 x | 53.5 x | 53.5 x |
| EV / EBITDA | - | -70.9 x | - | 296 x | -22.5 x | -17.4 x | -16.6 x |
| EV / FCF | 133 x | -64.1 x | -35.5 x | 49.7 x | -77.7 x | -38.6 x | -34.4 x |
| FCF Yield | 0.75% | -1.56% | -2.82% | 2.01% | -1.29% | -2.59% | -2.91% |
| Price to Book | 4.32 x | 3.79 x | 5.86 x | 6.13 x | 3.66 x | 4.64 x | 6.48 x |
| Nbr of stocks (in thousands) | 56,445 | 58,843 | 59,373 | 60,864 | 61,499 | - | - |
| Reference price 2 | 820.0 | 663.0 | 840.0 | 926.0 | 470.0 | 470.0 | 470.0 |
| Announcement Date | 10/09/20 | 09/09/21 | 08/09/22 | 13/09/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: July | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 100 | 2,100 | 1,400 | 22 | 2,350 | 1,000 | 540 | 540 |
| EBITDA 1 | - | - | -550.1 | - | 190.2 | -1,283 | -1,659 | -1,745 |
| EBIT 1 | -726 | 415 | -593 | -1,980 | 142.4 | -1,322 | -1,706 | -1,791 |
| Operating Margin | -726% | 19.76% | -42.36% | -9,000% | 6.06% | -132.2% | -315.93% | -331.67% |
| Earnings before Tax (EBT) 1 | -722 | 361 | -576 | -1,946 | 170.2 | -1,292 | -1,677 | -1,763 |
| Net income 1 | -721 | 347 | -582 | -1,948 | 168.4 | -1,294 | -1,679 | -1,765 |
| Net margin | -721% | 16.52% | -41.57% | -8,854.55% | 7.16% | -129.4% | -310.93% | -326.85% |
| EPS 2 | -16.85 | 6.440 | -10.02 | -32.92 | 2.800 | -21.20 | -27.30 | -28.70 |
| Free Cash Flow 1 | -781 | 349 | -608.7 | -1,404 | 1,135 | -372 | -748 | -840 |
| FCF margin | -781% | 16.62% | -43.48% | -6,381.82% | 48.3% | -37.2% | -138.52% | -155.56% |
| FCF Conversion (EBITDA) | - | - | - | - | 596.8% | - | - | - |
| FCF Conversion (Net income) | - | 100.58% | - | - | 674.17% | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/09/19 | 10/09/20 | 09/09/21 | 08/09/22 | 13/09/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: July | 2020 S1 | 2021 S1 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | 210 | 22 | 22 | - | - | - | 2,350 | - | 2,350 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -465 | -777 | -489 | -1,006 | -500 | -512 | -1,042 | 1,797 | -613 | 1,184 | -491 | -1,033 |
| Operating Margin | - | -370% | -2,222.73% | -4,572.73% | - | - | - | 76.47% | - | 50.4% | - | - |
| Earnings before Tax (EBT) 1 | -516 | -771 | -489 | -1,006 | -491 | -512 | -1,014 | 1,797 | -613 | 1,184 | -466 | -1,003 |
| Net income 1 | -518 | -776 | -490 | -1,007 | -493 | -513 | -1,016 | 1,796 | -612.1 | 1,184 | -467 | -1,005 |
| Net margin | - | -369.52% | -2,227.27% | -4,577.27% | - | - | - | 76.43% | - | 50.4% | - | - |
| EPS 2 | -9.920 | -13.52 | -8.320 | -17.07 | -8.310 | -8.620 | -17.03 | 30.08 | - | - | -7.660 | -16.45 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/03/20 | 11/03/21 | 09/12/21 | 10/03/22 | 09/06/22 | 14/12/22 | 08/03/23 | 14/06/23 | 13/09/23 | 13/09/23 | 13/12/23 | 13/03/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: July | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 2,485 | 10,667 | 10,166 | 8,877 | 10,217 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -781 | 349 | -609 | -1,404 | 1,135 | -372 | -748 | -840 |
| ROE (net income / shareholders' equity) | -32.3% | 5.2% | -5.5% | -20.7% | 1.9% | -15.1% | -23.8% | -33.1% |
| ROA (Net income/ Total Assets) | - | 5.17% | -5.25% | -19.2% | 1.43% | - | - | - |
| Assets 1 | - | 6,713 | 11,076 | 10,128 | 11,786 | - | - | - |
| Book Value Per Share 2 | 58.60 | 190.0 | 175.0 | 143.0 | 151.0 | 129.0 | 101.0 | 72.50 |
| Cash Flow per Share | -16.80 | 6.550 | -9.280 | -32.10 | 3.580 | - | - | - |
| Capex 1 | 4 | 226 | 89.1 | - | - | 40 | 40 | 40 |
| Capex / Sales | 4% | 10.76% | 6.36% | - | - | 4% | 7.41% | 7.41% |
| Announcement Date | 12/09/19 | 10/09/20 | 09/09/21 | 08/09/22 | 13/09/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.69% | 186M | |
| -2.61% | 88.47B | |
| +3.55% | 40.71B | |
| -13.97% | 32.43B | |
| +55.89% | 24.28B | |
| -15.91% | 15.52B | |
| -41.29% | 12.17B | |
| -15.19% | 12.01B | |
| -11.75% | 12B | |
| +7.87% | 8.87B |
- Stock Market
- Equities
- 4599 Stock
- Financials StemRIM